GENETICS AND EPIDEMIOLOGY: Edited by Isabella Annesi-Maesano and Antonella CianferoniEpidemiology of anaphylaxisTanno, Luciana Kasea,b,c; Demoly, Pascalb,c Author Information aHospital Sírio Libanês, São Paulo, Brazil bUniversity Hospital of Montpellier, Montpellier, and Desbret Institute of Epidemiology and Public Health, University of Montpellier, Montpellier, France cWHO Collaborating Center for Classification Scientific Support, Paris, France Correspondence to Luciana Kase Tanno, MD, PhD, Division of Allergy, Department of Pulmonology, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, 371, av. du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France. Tel: +33 467336107; fax: +33 467633645; e-mail: luciana.tann[email protected] Current Opinion in Allergy and Clinical Immunology: April 2021 - Volume 21 - Issue 2 - p 168-174 doi: 10.1097/ACI.0000000000000722 Buy Metrics Abstract Purpose of review To understand the current global epidemiological data of anaphylaxis and identify potential strategies to improve patients’ care and prevention. Recent findings Anaphylaxis mortality and morbidity statistics (MMS) may gain new perspectives with the implementation of the International Classification of Diseases (ICD)-11 in the forthcoming years. Improving the quality of epidemiological data related to anaphylaxis should clarify some areas of uncertainty about risk factors, leading to better targeting of strategies to protect those patients at risk, and support decision-making to facilitate healthcare planning and implementation of public health measures to prevent anaphylaxis. Summary Anaphylaxis is a complex noncommunicable diseases with adverse impact on health-related quality of life of patients and their carriers and a significant proportion of deaths may be preventable. It requires an integrated holistic plan to improve quality of healthcare and gathering accurate and comparable epidemiological data is key. Morbidity related to anaphylaxis seems to be increasing worldwide whereas mortality of anaphylaxis appears to be low and stable, but this still has great challenges in capturing quality anaphylaxis MMS. Improving the quality of epidemiological data related to anaphylaxis should clarify some areas of uncertainty about risk factors, leading to better targeting of strategies to protect those patients at risk. As knowledge derived from populations is key information for more realistic decision-making, the construction of the new section addressed to anaphylaxis in the ICD-11 will allow the collection of more accurate epidemiological data to support quality management of patients, and better facilitate healthcare planning to implement public health measures to prevent and reduce the morbidity and mortality attributable to these conditions. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.